Damon Demady is an accomplished drug development leader with extensive experience in the biotechnology and pharmaceutical industry. With a Ph.D. in pharmacology from the University of Michigan Medical School and a BA in biochemistry from Colgate University, he has a proven track record of successfully developing therapies in various therapeutic areas, including oncology, immunology, neurology/pain, orphan diseases, and cardiovascular. Damon is highly skilled in pharmacology, toxicology, regulatory affairs, business development, due diligence, bioanalytical sciences, good laboratory practices, cell therapy, biologics (all formats), and small molecules. Throughout his career, he has been a key contributor in primary authoring regulatory submissions for drug applications and has a wide range of peer-reviewed publications, a testament to his research and leadership skills. Damon's expertise has been recognized by organizations such as Rubius Therapeutics, where he serves as Senior Director and Head of Preclinical Development, and by industry leaders such as Novartis Institutes for Biomedical Research and Biogen Idec, where he previously held crucial roles.